The methylation status of the MGMT gene promoter is used to predict the response of gliomas to alkylating chemotherapy agents.26 Heterogeneity in the methylation status of tumor cells within individual gliomas has been described.27,28 The extent of heterogeneity in MGMT gene promoter methylation within gliomas requires further evaluation. This evidence concerns the gene MGMT and glioma.